News Sentiment

OKYO sentiment intelligence

OKYO Pharma Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.69 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+7.6% over one week, +11.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

H.C. Wainwright Maintains OKYO Pharma(OKYO.US) With Buy Rating, Cuts Target Price to $5

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 7.6% Price confirming higher
Trend fit Trend inactive 11.2% over four weeks
Fair value 1.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 21
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 7
Investing.com 3
Proactive 3
The Globe and Mail 2
GlobeNewswire 2
Proactive financial news 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 9
Analyst action 2
Regulatory and legal 2
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47
Investing.com Canada Direct company coverage

OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com

OKYO Pharma has appointed Marta Sacchetti, MD, PhD, to its Scientific Advisory Board. Dr. Sacchetti is an Associate Professor of Ophthalmology at Link University in Rome and previously served as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceut

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 11:39
Source
Investing.com Canada
The Manila Times Direct company coverage

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

OKYO Pharma Limited has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an international expert in ocular inflammatory and degenerative diseases. Dr. Sacchetti's expertise in neuro-inflammatory corneal diseases will be crucial for the company's

Tone
Positive 72/100
Event
Market update
Published
19 May 2026 10:39
Source
The Manila Times
Stock Titan Direct company coverage

OKYO Pharma (OKYO) deepens NCP program with new advisory board expert

OKYO Pharma announced the expansion of its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti, an expert in corneal and ocular surface diseases, to bolster its neuropathic corneal pain (NCP) program. The company is developing Urcosimod, an investigational drug

Tone
Positive 65/100
Event
Regulatory and legal
Published
19 May 2026 10:39
Source
Stock Titan
Proactive financial news Direct company coverage

OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board

OKYO Pharma Ltd (NASDAQ:OKYO) has appointed Dr. Marta Sacchetti, an ophthalmology specialist, to its Scientific Advisory Board. This addition aims to strengthen the company's clinical programs in neuropathic corneal pain and inflammatory eye diseases, leveraging Dr. Sacchetti's e

Tone
Positive 71/100
Event
Market update
Published
19 May 2026 09:58
Source
Proactive financial news
Market source Direct company coverage

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

OKYO Pharma Limited's CEO, Robert J. Dempsey, and CSO, Raj Patil, PhD, will present at upcoming scientific conferences in May. Dempsey will speak at Eyecelerator on addressing unmet needs in corneal and anterior segment diseases, while Patil will present at the ARVO Annual Meetin

Tone
Positive 70/100
Event
Market update
Published
30 Apr 2026 03:09
Source
Market source
MarketBeat Direct company coverage

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) experienced a significant 31.9% increase in short interest in April, reaching 272,194 shares. This represents approximately 1.1% of the company's shares sold short, with a days-to-cover ratio of 2.5 days. The company's stock is curr

Tone
Negative 35/100
Event
Market update
Published
30 Apr 2026 02:10
Source
MarketBeat